Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, the defendants made materially false and misleading statements about masofaniten's efficacy [2]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone, contrary to what was communicated to investors [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the clinical and commercial prospects of masofaniten were overstated [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is March 25, 2025, and they are encouraged to register without delay [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices [4]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [4].